^
    1m
    AugMMent: GMMG-HD11/DSMM XXI/64007957MMY3010 (clinicaltrials.gov)
    P3, N=399, Not yet recruiting, University of Heidelberg Medical Center
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • melphalan • Tecvayli (teclistamab-cqyv)
    1m
    Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) (clinicaltrials.gov)
    P1, N=12, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jan 2028 --> Aug 2028 | Trial primary completion date: Jan 2028 --> Aug 2028
    Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
    |
    Darzalex (daratumumab) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • idarubicin hydrochloride
    2ms
    TRIlogy-7: A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned (clinicaltrials.gov)
    P3, N=1000, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • ramantamig (JNJ-5322) • dexamethasone injection
    2ms
    Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis (clinicaltrials.gov)
    P1, N=21, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2027 --> Jun 2026 | Trial primary completion date: May 2027 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone injection
    2ms
    Dexamethasone activates anti-tumor immunity in multiple myeloma by dismantling the GR-PPP1CB complex to restore STING/IRF3 signaling. (PubMed, J Immunother Cancer)
    This study uncovers a glucocorticoid-sensitive inhibitory axis wherein GR-PPP1CB constitutively suppresses STING-TBK1-IRF3 signaling in MM. DXM relieves this suppression, reactivating innate anti-tumor immunity. PP1 inhibition represents a promising therapeutic strategy to enhance anti-myeloma immunity and overcome immune evasion.
    Journal • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CGAS (Cyclic GMP-AMP Synthase)
    |
    bortezomib • Darzalex (daratumumab) • dexamethasone • salubrinal
    2ms
    KarMMa-3: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=386, Completed, Celgene | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> Apr 2026 | Trial primary completion date: Apr 2027 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Abecma (idecabtagene vicleucel)
    2ms
    Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. (PubMed, Kidney Med)
    Daratumumab-based induction therapy resulted in a partial renal response (urinary protein-creatinine ratio of 0.7 g/g)...To our knowledge, this case represents only the second reported case of HTRA1-MN occurring in the setting of monoclonal gammopathy, the first in multiple myeloma, and a rare example of a nonmonotypic MN in this context. Temporal proximity and partial response to anti-plasma cell therapy suggest a possible paraneoplastic relationship, although a causal relationship remains unproven.
    Journal
    |
    HTRA1 (HtrA Serine Peptidase 1)
    |
    Darzalex (daratumumab)
    2ms
    ALLG MM21: Daratumumab-lenalidomide-dexamethasone (DRd) salvage for newly diagnosed Multiple Myeloma patients who fail bortezomib induction therapy (ACTRN12618001490268)
    P2, N=50, Completed, Australiasian Leukaemia and Lymphoma Group | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone
    2ms
    EMN2868284528MMY3005: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (2023-507632-20-00)
    P2/3, N=440, Recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • Carvykti (ciltacabtagene autoleucel)
    2ms
    Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=0, Withdrawn, UNC Lineberger Comprehensive Cancer Center | N=39 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone
    2ms
    Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. (PubMed, Ann Med Surg (Lond))
    When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.
    Journal
    |
    CRBN (Cereblon)
    |
    Darzalex (daratumumab) • pomalidomide • forimtamig (RG6234)
    2ms
    MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2027 --> Oct 2025
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • Ogsiveo (nirogacestat) • Tecvayli (teclistamab-cqyv)